Detailansicht

Wissensnetz

Person

Tobias Ruck (1985-)

Arzt

Name	Tobias Ruck
Zeit	1985- (Lebensdaten)
Ort	Stuttgart (Geburtsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	PD Dr. med.
Beruf	Arzt (charakteristischer Beruf) Neurologe
Beziehung	Universitätsklinikum Düsseldorf
Weitere Angaben	Diss. an der Medizinischen Fakultät der Univ. Würzburg (2014); Assistenzarzt der Klinik für Neurologie des Universitätsklinikums Münster
Quelle	Dissertation
Datensatztyp	Person
GND-Nummer	1050955498
Datensatz-ID	1050955498
Beteiligt an alle anzeigen Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison Cloxyquin activates hTRESK by allosteric modulation of the selectivity filter Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis Incidence, Prevalence, Hospitalization Rates, and Treatment Patterns in Myasthenia Gravis: A 10-Year Real-World Data Analysis of German Claims Data Ätiologische und bildmorphologische Analyse intrazerebraler Hirnblutungen Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients Eculizumab versus rituximab in generalised myasthenia gravis Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients Effect of Capsaicinoids on Neurophysiological, Biochemical, and Mechanical Parameters of Swallowing Function A sum score to define therapy-refractory myasthenia gravis: a German consensus Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation Effect of capsaicinoids on neurophysiological, biochemical, and mechanical parameters of swallowing function A role for TASK2 channels in the human immunological synapse Dysphagia as Isolated Manifestation of Jo-1 Associated Myositis? Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation Nanomechanics of the endothelial glycocalyx contribute to Na+-induced vascular inflammation Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? Modernes Therapiemanagement bei RRMS : mit einer individuell optimierten Therapieentscheidung MS-Patienten so früh und so wirksam wie möglich behandeln Enzephalitogene Eigenschaften und gesteigerte migratorische Kapazität von CD4 + NKG2D + T Zellen in autoimmunen, entzündlichen Prozessen des zentralen Nervensystems

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Tobias Ruck (1985-)

Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment

Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison

Cloxyquin activates hTRESK by allosteric modulation of the selectivity filter

Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis

Incidence, Prevalence, Hospitalization Rates, and Treatment Patterns in Myasthenia Gravis: A 10-Year Real-World Data Analysis of German Claims Data

Ätiologische und bildmorphologische Analyse intrazerebraler Hirnblutungen

Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses

Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis

Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses

Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

Eculizumab versus rituximab in generalised myasthenia gravis

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

Effect of Capsaicinoids on Neurophysiological, Biochemical, and Mechanical Parameters of Swallowing Function

A sum score to define therapy-refractory myasthenia gravis: a German consensus

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation

Effect of capsaicinoids on neurophysiological, biochemical, and mechanical parameters of swallowing function

A role for TASK2 channels in the human immunological synapse

Dysphagia as Isolated Manifestation of Jo-1 Associated Myositis?

Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation

Nanomechanics of the endothelial glycocalyx contribute to Na+-induced vascular inflammation

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

Modernes Therapiemanagement bei RRMS : mit einer individuell optimierten Therapieentscheidung MS-Patienten so früh und so wirksam wie möglich behandeln

Enzephalitogene Eigenschaften und gesteigerte migratorische Kapazität von CD4 + NKG2D + T Zellen in autoimmunen, entzündlichen Prozessen des zentralen Nervensystems